SCHEMBL6482701

SCHEMBL6482701

Fc1ccc2oc3ccc([CH]c4ccc5ccccc5c4)cc3c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2A6 P11509 1/20 0.47
TNKS O95271 1/20 0.39
RELA Q04206 1/20 0.39
CBX7 O95931 1/20 0.38
CDYL Q9Y232 1/20 0.38
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PTGES2 Q9H7Z7 2/20 0.36
PPARG P37231 1/20 0.36
NQO2 P16083 1/20 0.36
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35
GABRA1 P14867 2/20 0.35
GABRB1 P18505 2/20 0.35
GABRG2 P18507 2/20 0.35
GABRB3 P28472 2/20 0.35
GABRA5 P31644 2/20 0.35
GABRA3 P34903 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6493939 0.81 KMT2A (0.39) TNKSKDM4EALDH1A1L3MBTL1PPARG
SCHEMBL10466215 0.78 CYP1A2 (0.58) CYP1A2CYP2A6RELAKDM4EALDH1A1
SCHEMBL6494130 0.76 CYP1A1 (0.36) CYP1A2CYP2A6TNKSPTGES2PPARG
SCHEMBL6493354 0.75 NFE2L2 (0.42) TNKSPTGES2GABRPGABRDGABRA1
SCHEMBL6485706 0.75 RXFP1 (0.36) CYP1A2TNKSKDM4EALDH1A1PTGES2
SCHEMBL25011813 0.74 GABRP (0.52) TNKSKDM4EALDH1A1GABRPGABRD
SCHEMBL2838139 0.74 RELA (0.62) CYP1A2CYP2A6RELAKDM4EALDH1A1
SCHEMBL6765610 0.74 CYP1A2 (0.44) CYP1A2CYP2A6TNKSCBX7CDYL
SCHEMBL6497221 0.73 MEN1 (0.38) TNKSKDM4EALDH1A1GABRPGABRD
SCHEMBL5848938 0.73 MAPT (0.59) CYP1A2TNKSKDM4EALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 CYP1A2 2938/4885CYP2A6 1447/4885TNKS 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.